Search
Influenza B virus B/Brisbane/60/2008 antigen (formaldehyde inactivated)
go.drugbank.com/drugs/DB10794ApprovedInvestigationalWithdrawnInactivated virus cannot replicate, and therefore cannot cause disease from infection, even in immunocompromised individuals. … In contrast, live vaccines are produced from "wild-type" or disease-causing viruses that have been attenuated, or weakened, through various laboratory techniques.
Mixtures: Medical Provider Single Use EZ Flu Shot Fluzone 2016-2017Bordetella pertussis filamentous hemagglutinin antigen (formaldehyde inactivated)
go.drugbank.com/drugs/DB10788ApprovedInvestigationalBordetella pertussis filamentous hemagglutinin antigen (formaldehyde inactivated) is a vaccine that contains inactivated acellular pertussis antigen that is isolated from Bordetella pertussis culture.
Mixtures: Repevax Injektionssuspension in einer Fertigspritze, -POLIO SUSPENSION FOR INJECTION IN PRE-FILLED SYRINGEDoxercalciferol
go.drugbank.com/drugs/DB06410ApprovedInvestigationalDoxercalciferol is indicated for the treatment of secondary hyperparathyroidism in patients with chronic kidney disease on dialysis, as well as for the treatment of secondary hyperparathyroidism in patients … Doxercalciferol is a synthetic vitamin D2 analog that undergoes metabolic activation in vivo to form 1α,25-dihydroxyvitamin D2 (1α,25-(OH)2D2), a naturally occurring, biologically active form of vitamin
Tralokinumab
go.drugbank.com/drugs/DB12169ApprovedInvestigationalUS in December 2021. … Tralokinumab was first approved for the treatment of atopic dermatitis by the EMA in June 2021, under the brand name Adtralza (Leo Pharma), and was subsequently approved in Canada in October 2021 and the
Eliglustat
go.drugbank.com/drugs/DB09039ApprovedInvestigational[L41404,A7634] Eliglustat was approved by the FDA in August 2014 as an oral substrate reduction therapy for the first-line treatment of type 1 Gaucher disease. … [A3752,L41404] Gaucher disease is a rare genetic disorder characterized by the deficiency of acid β-glucosidase, an enzyme that converts glucosylceramide into glucose and ceramide.
Synonyms: N-[(1R,2R)-1-(2,3-Dihydro-1,4-benzodioxin-6-yl)-1-hydroxy-3-(1-pyrrolidinyl)-2-propanyl]octanamideDiphenoxylate
go.drugbank.com/drugs/DB01081ApprovedIllicitInvestigationalA meperidine congener used as an antidiarrheal, usually in combination with atropine. At high doses, it acts like morphine. … This medication is classified as a Schedule V under the Controlled Substances Act by the Food and Drug Administration (FDA) and the DEA in the United States when used in preparations.
Etuvetidigene Autotemcel
go.drugbank.com/drugs/DB17593ApprovedInvestigationalEtuvetidigene autotemcel is an autologous gene therapy which includes hematopoietic stem cells (HSCs) that have been genetically modified ex vivo. … [A274878] The WAS protein is expressed on non-erythroid hematopoietic cells and regulates the function of actin filaments in the cytoskeleton.[A274878]
Iron protein succinylate
go.drugbank.com/drugs/DB11209ApprovedMixtures: PR Natal 430 ec, PR Natal 400 ecBuformin
go.drugbank.com/drugs/DB04830ApprovedWithdrawnIt was withdrawn from the market in most countries due to a high risk of causing lactic acidosis. … Buformin is an anti-diabetic drug of the biguanide class, chemically related to metformin and phenformin.
Categories: Drugs Used in DiabetesSolifenacin
go.drugbank.com/drugs/DB01591ApprovedInvestigational[L7511] Solifenacin was granted FDA approval on 19 November 2004.[L7511] … Solifenacin is a competitive muscarinic receptor antagonist indicated to treat an overactive bladder with urinary incontinence, urgency, and frequency.
Categories: Drugs Used in Benign Prostatic Hypertrophy